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Summary
Biologics are effective and have a good safety profile in
the treatment of inflammatory bowel disease. Biosimilars
have recently become available as treatment option. They
are biological agents that are highly similar to the origi-
nal biologic compound in their structure, biological activity,
efficacy and safety. This position paper summarises cur-
rent knowledge on biosimilars and presents its statements
on regulatory issues and clinical situation in order to pro-
vide clinicians adequate information for them to reach in-
formed and appropriate shared decision-making with their
patients.
Keywords: inflammatory bowel disease, biologics,
biosimilars
Introduction
Since the introduction of infliximab in 1999, biologics
have revolutionised medical treatment in inflammatory
bowel disease (IBD), demonstrating high efficacy and a
good safety profile [1, 2]. Today, physicians may choose
from a variety of compounds to tailor their treatment to
the individual patient. A biosimilar is a biological medi-
cine highly similar to another, already approved biological
medicine (called “reference product”) in terms of structure,
biological activity and efficacy, safety and immunogenicity
profile. In Europe, the first biosimilar, a recombinant hu-
man growth hormone, was authorised in 2006 and as of
today, over 40 biosimilars have entered the market. CT-
P13 (manufactured by Celltrion, South Korea) was the first
infliximab biosimilar to be approved by Swissmedic, the
Swiss Regulatory Agency for Therapeutic Products [3].
By then, CT-P13 had already been approved by the Euro-
pean Medicines Agency (EMA) and later also received ap-
proval by the US Food and Drug Administration (FDA).
Patents for many other biologics will expire in the near fu-
ture and development of several biosimilars is underway.
Therefore, physicians should be aware of the definition,
approval process as well as the biochemical and clinical
parameters that distinguish biosimilars from the reference
product. Balanced information on biosimilars is paramount
in making appropriate decisions for their patients.
This position statement by the Inflammatory Bowel Dis-
ease Net (IBDnet), an official working group of the Swiss
Society of Gastroenterology, discusses several key aspects
in the approval process and the clinical use of biosimilars.
Using a Delphi-like technique, a panel of eight IBDnet del-
egates anonymously answered a total of 16 questions. All
questions were rated using a Likert scale from 1 (strong-
ly disagree) to 4 (strongly agree). Sufficient consensus was
reached when the overall rating was 3 or higher, and the
statement was accepted. In a final session, all statements
were finalised on 18 June 2018 in Bern, Switzerland.
Regulatory process
– To grant a licence for a biosimilar, Swissmedic requires
biosimilarity, which means sufficient similarity of mole-
cular structure, biological activity, efficacy, safety and
immunogenicity.
Swissmedic is the regulatory agency for all medicinal
products and grants official authorisation before medicines
can enter the market. Current Swissmedic guidance docu-
mentation on biosimilars requires that an applicant prod-
uct is sufficiently similar with respect to structure, biolog-
ical activity, efficacy, safety and immunogenicity in order
to rule out relevant clinical differences with sufficient reli-
ability [4]. This is similar to the requirements of the FDA,
which allow “no clinically meaningful differences between
the biological product and the reference product in terms
of safety, purity, and potency” and the clarification by the
EMA that a biosimilar must demonstrate similarity to the
reference product in terms of quality characteristics, bio-
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logical activity, safety and efficacy based on a comprehen-
sive comparability exercise [5, 6].
Unlike the approval of novel biologics, the approval path-
way for biosimilars places more emphasis on comparative
analytical data than on clinical studies. Biologics are very
large molecules produced by living cells, so biosimilars are
unlike small-molecule generics. Biosimilars, produced by
a different cell clone with a reconstituted DNA template
under different growth conditions, will never be identical
to the reference product. Differences may arise from var-
ious steps within the manufacturing process and result in
heterogeneity of the complex molecular structure [7, 8].
Thus, biosimilars are not generic equivalents of the refer-
ence product and require additional characterisation [4–6].
The molecular structure has to be analysed to ensure equiv-
alent composition, especially since posttranslational mod-
ifications may differ in the various cell lines used for
biosimilar production. This was the case for infliximab,
which showed posttranslational changes to the Fc receptor,
and only after additional in vitro studies was the manufac-
turer able to demonstrate that these differences were not
of clinical significance [9, 10]. The observed differences
from the originator have caused concern among physicians
about the efficacy and safety of biosimilars [11, 12].
Although every biosimilar applicant has to demonstrate
sufficient similarity in structure, biological activity, effica-
cy, safety and immunogenicity in order to receive regulato-
ry approval, clinical efficacy has only to be proven in one
indication of the reference product. In the case of CT-P13,
Celltrion submitted one comparative clinical study in pa-
tients with rheumatoid arthritis and one supportive study in
patients with ankylosing spondylitis that confirmed similar
efficacy [13, 14]. Based on comparative studies, regulatory
agencies will then decide if additional confirmatory clin-
ical trials are warranted or if extrapolation of indications
is enough to guarantee approval for each indication of the
reference product.
In IBD, no specific trials have been conducted with
biosimilars prior to approval. So far, the body of evidence
suggests that the first infliximab biosimilar CT-P13 has
similar efficacy and safety profiles to the reference inflix-
imab [15–44], but some studies have been criticised [45]
and strict pharmacovigilance is still warranted in the post-
marketing setting.
Extrapolation of indications
– Extrapolation of indications includes detailed biochem-
ical and physicochemical evaluation of the biosimilar
compound, clinical data on pharmacokinetic and phar-
macodynamic equivalence to the reference product and
clinical efficacy in one relevant sensitive patient popu-
lation.
Extrapolation is the regulatory and scientific process of ap-
plying clinical efficacy and safety data of the biosimilar
derived from comparative studies in one therapeutic indi-
cation to all indications of the reference product. This is a
key concept in the approval process of biosimilars. How-
ever, regulatory agencies base their decision to allow ex-
trapolation of indications not only on clinical data, but al-
so on the totality of evidence, which also includes data on
the structural and physicochemical evaluation of the com-
pound, as well as data on pharmacokinetic and pharmaco-
dynamic equivalence to the reference product. Swissmedic
states that an extrapolation of indications and dosage rec-
ommendations from the reference product to the biosimilar
is possible only if it is scientifically justified and the as-
sociated risk to patient safety is acceptable [4]. The com-
parability between the biosimilar and the reference prod-
uct, and thus the extrapolation to further indications and
dosage recommendations, must be demonstrated in at least
one sensitive indication and dosage or, if required, sepa-
rately for each of the indications and dosage recommenda-
tions applied for.
To define the target population with the most sensitive dis-
ease may pose some difficulties. In order to demonstrate
clinical equivalence, the therapeutic indication for the ref-
erence with the smallest difference from placebo should
be selected, maximising the sensitivity to treatment effects.
For the clinical trials of CT-P13, ankylosing spondylitis
and rheumatoid arthritis were selected. First, in a phase I
randomised double-blind study, equivalent pharmacokinet-
ics, and tolerability, safety and efficacy of CT-P13 compa-
rable to the reference infliximab in patients with ankylos-
ing spondylitis were demonstrated [14]. Then, in a phase
III randomised double-blind study, clinical efficacy was
tested in patients with rheumatoid arthritis [13]. Again,
this study showed comparable results for CT-P13 and the
reference infliximab. However, because concomitant
methotrexate was used in the PLANETRA, study patients
with the “most sensitive indication” for comparison might
not have selected.
Patients with IBD represent a very different patient popula-
tion. In the randomised double-blind parallel-group NOR-
SWITCH study, which tested interchangeability from the
original infliximab to the biosimilar CT-P13, no significant
difference in efficacy and safety was detected in the study
population overall [22]. However, less than half of the
study population consisted of patients with IBD (Crohn’s
disease 32% and ulcerative colitis 19%). Although the
study was not powered for subgroup analysis, patients with
Crohn’s disease just barely fulfilled the noninferiority mar-
gin of 15%. In all other patient groups, the differences were
much smaller. CT-P13 has decreased affinity for FcγRIII
receptors and it is biologically plausible that this is linked
to a decreased efficacy of CT-P13 in Crohn’s disease [45].
Usually, in order to demonstrate similar efficacy of a new
compound compared with the reference product, noninfe-
riority trials allow only 10% difference in the defined end-
points. This has raised some concern on the principle of
extrapolation of indication for this class of biologics. Ac-
cordingly, Health Canada initially argued that differences
in antibody-dependent cellular cytotoxicity (ADCC), afu-
cosylation, and FcγRIIIa receptor binding were different
for CT-P13. Full approval for the entire range of indica-
tions was subsequently granted only after additional data
on physicochemical and biological properties, mechanism
of action and clinical experience with the reference prod-
uct were provided [46, 47].
There is consensus that extrapolation of indication needs
convincing scientific justification and Swissmedic has is-
sued guidance on the requirements that need to be fulfilled
[4]. The concept of extrapolation will avoid unnecessary
repetitions of studies and will save time and resources in
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the regulatory process. Biosimilars are approved on a case-
by-case and agency-by-agency basis after evaluating the
totality of evidence from the entire development program.
Approved and future biosimilars for IBD in Switzer-
land
Currently, the infliximab biosimilar CT-P13 is the only
compound approved in Switzerland for the use in IBD. It
is produced by Celltrion (South Korea) and is marketed as
Inflectra® by Pfizer Europe and as Remsima® by iQone
(Germany). More biosimilars in IBD have already been
approved by the EMA and the FDA (table 1), but not in
Switzerland. However, this is likely to change in the near
future, as a wave of biosimilars has just started to roll in
and within the next years, the greater part of current rev-
enues of biotech companies will likely be subject to com-
petition from biosimilars (table 2).
Prescription, interchangeability and substitu-
tion
Prescription
– All biologics and biosimilars should be prescribed by
brand name and not by international nonproprietary
name.
Biosimilars should be clearly distinguishable from the ref-
erence product, and competing biosimilars and should be
easily identifiable for patients, doctors and pharmacists
alike. The international nonproprietary name (INN) of a
biosimilar is not different from the original product, such
as infliximab, which might be problematic for the trace-
ability, especially in post-marketing studies and monitor-
ing programmes [48]. It is paramount for patient safety that
Table 1: Biosimilars approved by the EMA and/or FDA.
Brand name (molecule) INN (with suffix) Regulatory agencies Manufacturer / marketing Authorisation date
Inflectra®
(CT-P13)
Infliximab
Inflximab-dyyb
EMA
FDA
Pfizer Europe MA EEIG
Celltrion Inc
Sept 2013
April 2016
Remsima®
(CT-P13)
Infliximab EMA Celltrion Healthcare Hungary Kft Sept 2013
Flixabi®
(SB-2)
Infliximab EMA Samsung Bioepis UK Ltd (SBUK) May 2016
Renflexis®
(SB-2)
Infliximab-abda FDA Samsung Bioepis Co Ltd. May 2017
Ixifi®
(GP1111)
Infliximab-qbtx FDA Pfizer Inc. Dec 2017
Zessly®
(PF-06438179)
Infliximab EMA Sandoz GmbH May 2018
Hulio®
(FKB327)
Adalimumab EMA Mylan S.A.S. Sep 2018
Idacio®
Kromeya®
(MSB11022)
Adalimumab EMA Fresenius Kabi Deutschland Apr 2019
Amgevita®
Amjevita®
(ABP 501)
Adalimumab
Adalimumab-atto
EMA
FDA
Amgen Europe b.V.
Amgen Inc.
Mar 2017
Sept 2016
Hyrimoz®
(GP2017)
Adalimumab
Adalimumab-adaz
EMA
FDA
Sandoz GmbH
Novartis
Jul 2018
Oct 2018
Cyltezo®
(BI 695501)
Adalimumab-adbm FDA Boehringer Ingelheim Aug 2017
Imraldi®
Hadlima®
(SB-5)
Adalimumab
Adalimumab-bwwd
EMA
FDA
Samsung Bioepis NL B.V.
Samsung Bioepis Co Ltd.
Aug 2017
Mar 2019
EMA = European Medicines Agency; FDA = US Food and Drugs Administration; INN = international nonproprietary name Exemptia (ZRC-3197) adalimumab biosimilar is licensed
in India only
Table 2: Biosimilars under development for possible use in inflammatory bowel disease.
Molecule Manufacturer Current status
Infliximab BOW015* Epirus Biopharmaceuticals Phase III study
NI-071 Nichi-Iko Pharmaceuticals Phase III study
STI-002 MabTech / Sorrento Therapeutics Preclinical
Adalimumab CHS-1420 Coherus Phase III study
M923 Momenta/Baxalta Phase III study
LBAL LG Life Sciences / Mochida Pharmaceuticals Preclinical
MYL-1401A Mylan Inc. Preclinical
PF-06410293 Pfizer Inc. Phase III study
BCD-057 Biocad Preclinical
ONS-3010 Oncobiologics Preclinical
Golimumab BOW100 Epirus Biopharmaceuticals Preclinical
Certolizumab PF6688 Pfenex Preclinical
Xcimanze Xbrane Preclinical
* BOW015 infliximab biosimilar is licensed in India only
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the nomenclature for biosimilars is unique, and product in-
formation and batch manufacturing data allow for stringent
pharmacovigilance.
The World Health Organization (WHO) recommendation
proposes the addition of a unique identification code to
identify biosimilars marketed under the INN. This qualifier
would consist of a random addition of four consonants to
the INN to label the manufacturer of the compound [49].
Similarly, the FDA recommends using a suffix of four low-
ercase letters to be added to the INN, three of which are
distinct to the manufacturer of a given biosimilar [50]. In
Europe, biosimilars share the same INN with the refer-
ence product. However, the EMA has applied the use of
brand names in conjunction with the INN to distinguish
between different manufacturers and allow traceability [6].
Swissmedic requires the INN to comply with WHO stan-
dards [4]. Thus, the name of a biosimilar must be either a
creative name or the INN linked to a company name in or-
der to easily identify biosimilars or the reference product.
Naming conventions are currently not consistent world-
wide and the identification of biosimilars will remain a
challenge. Global harmonisation is more than desirable in
this matter as it has a direct impact on pharmacovigilance
data and also on monitoring programmes for interchange-
ability, substitution and in the future possibly reimburse-
ment [51].
Interchangeability
– Prescribing physicians can interchange Inflectra® and
Remsima®. Interchanging current Remicade® therapy
with Inflectra® or Remsima® requires close efficacy and
safety monitoring.
“Interchangeability” is the medical practice of changing
one medicine for another. Interchangeability is not auto-
matically granted after regulatory approval of a biosimilar,
but is designated after an additional review process by the
regulatory agencies. In Europe, this is regulated on a na-
tional level, not by the EMA [52]. In contrast, the FDA
has the authority to designate a biosimilar interchangeable
with its reference product [53]. In order to be interchange-
able, guidance by the FDA states that a biological prod-
uct must be biosimilar, to have the same expected clini-
cal effects and safety profile in any given patient, and to
carry the similar risk when switching or continuing with
the originator product if given more than once. In Switzer-
land, similar to other European countries, authorisation
by Swissmedic does not contain any statement regarding
whether a biosimilar can be used interchangeably with the
reference product. It is recommended, that such a decision
be made exclusively by the prescriber, i.e., the attending
physician [4].
Inflectra® and Remsima® are identical biological products
(both CT-P13) which are manufactured under identical
conditions by the same manufacturer in South Korea (Cell-
trion), but are marketed by two different companies in
Switzerland (Pfizer, iQone). As they are bioidentical,
rather than biosimilar, a prescribing physician may inter-
change between them. However, when interchanging cur-
rent Remicade® therapy with Inflectra® or Remsima®,
close monitoring of efficacy and safety is required. Also, it
is important to consider that with more independently de-
veloped biosimilars entering the market, the issue of inter-
changeability not only with the reference product but al-
so among biosimilars will become even more important,
especially since head-to-head comparisons of different
biosimilars are unlikely to be carried out. For example,
comparison data from erythropoietin biosimilars showed
differences in pharmacodynamic properties among them,
resulting in different dosing requirements [54].
The regulatory framework and post-marketing pharma-
covigilance by the manufacturers must be stringent and re-
assure prescribers that an approved biosimilar can be ad-
ministered safely and is in fact interchangeable with the
reference product.
Substitution
– Dispensing pharmacists are strongly encouraged not to
substitute Remicade®, Inflectra® and Remsima®.
Substitution describes the nationally regulated practice of
dispensing one medical product instead of another inter-
changeable product at the pharmacy. This policy has been
adopted in Switzerland for generic medication: pharma-
cists can substitute the original product at their discretion.
Only if the physician has specifically prescribed an origi-
nal product, must pharmacists inform the prescriber about
the dispensed product in the event of substitution. For bio-
logics, recommendations by Swissmedic advocate against
automatic substitution by leaving the decision to inter-
change biological products exclusively with the prescrib-
ing physician [4]. Remicade® and Inflectra®/Remsima®
cannot be substituted by the dispensing pharmacist without
consent of prescribing clinician. There is general concern
that automatic substitution might lead to dispensing mis-
takes that might potentially harm patients, especially when
interchangeability has not directly been demonstrated in
many specific clinical settings of a given disease. Also,
there is doubt about pharmacovigilance, as pharmacists are
not obliged to track batches (in contrast to physicians). It
is known from the originator that batch-to-batch variations
exist, and this will also be the case for any biosimilar [55].
Each biosimilar product should be easily distinguishable
from the reference product and other biosimilars to ensure
appropriate use, traceability and accurate reporting of ad-
verse drug reactions. Otherwise a true signal on a biosim-
ilar may be adjudicated to the safety database of the ref-
erence product, for example when the INN is used, and
thereby go undetected in the system. Only the exchange of
bioidenticals such as Inflectra® and Remsima® is consid-
ered unproblematic as they originate from the same biolog-
ical material and manufacturing process.
Efficacy
– Elective non-medical switch from Remicade® to CT-
P13 does not impact efficacy. Head-to-head trials
demonstrated comparable efficacy of Remicade® and
CT-P13.
Since the approval of CT-P13, reassuring data on its effi-
cacy compared with the reference product has been report-
ed in both non-IBD [56, 57] and IBD patients [15–43]. In
IBD, real life data have emerged mainly from prospective
open-label studies in stable patients on maintenance ther-
apy who were switched to CT-P13, but also from obser-
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vational studies in patients during induction therapy and
from randomised controlled trials [22, 37, 43]. So far, these
studies did not observe significant differences between the
biosimilar and the reference product, demonstrating simi-
lar efficacy and safety for CT-P13. None of these studies
reported differences in safety outcomes. Medium- and
long-term data from several cohorts have also emerged and
showed comparable effects in terms of efficacy, safety and
immunogenicity.
In the PROSIT-BIO multicentre observational cohort, pa-
tients who were either naïve to biologics, or had been pre-
viously exposed to or had been switched from original in-
fliximab were included [21]. Efficacy estimates on 434
patients who received a defined minimum of treatments
were not different for naïve (74%), pre-exposed (62%)
and switch patients (79%) after 24 weeks. In an extension
study of the same cohort, the primary nonresponse rate
was 6.4%, and 25.6% lost response during follow-up [33].
Among those who had responded to infliximab induction
therapy, treatment persistence was similar in the three pa-
tient groups. Also, in another single-centre prospective ob-
servational study, no difference in terms of clinical re-
mission (58 vs 47%), clinical response (13 vs 11%) or
secondary loss of response (25 vs 42%) was detected in pa-
tients who switched to CT-P13 (n = 191) compared with
those who continued on Remicade® (n = 19) during 12
months follow-up [28]. Data for patients with fistulising
Crohn’s disease are scarce.
A Korean post-marketing study in 173 patients that also in-
cluded 12 patients with fistulising Crohn’s disease showed
clinical remission in 50% and clinical response in 67% af-
ter 30 weeks of treatment with CT-P13 [16]. No differ-
ence was seen between naïve patients and those who were
switched to CT-P13.
A meta-analysis including 11 observational studies calcu-
lated that the pooled clinical response rates for Crohn’s
disease and ulcerative colitis after induction therapy with
CT-P13 were 79% (95% confidence interval 65–88%) and
74% (65–82%), respectively, and during maintenance ther-
apy (24–30 weeks) were 77% (67–86%) and 77%
(67–85%), respectively [58]. This was comparable to the
published response rate for the originator Remicade®. Sus-
tained clinical response in patients who were switched
from Remicade® to CTP-13 after 48–63 weeks was re-
ported to be 75% (44–92%) for Crohn’s disease and 83%
(19–99%) for ulcerative colitis. Again, this was compara-
ble to the expected annual loss of response rates of approx-
imately 10–20% for Remicade® [59, 60].
Long-term data on patients who were switched to CT-P13
are limited. A prospective open-label nationwide cohort in-
cluding 354 patients (209 with Crohn’s disease) on CT-
P13 found no difference in clinical efficacy after 54 weeks.
Specifically, clinical remission and clinical response rates
for Crohn’s disease and ulcerative colitis were 65%/81%
and 50%/66%, respectively [26]. Response rates in in-
fliximab-naïve patients (54%/73% and 47%/51%, respec-
tively) were significantly higher than in those with pri-
or exposure to anti-tumour necrosis factor (TNF) agents
(32%/44% and 27%/42%, respectively).Concomitant use
of azathioprine did not affect clinical efficacy.
Another prospective observational open-label multicentre
study from Sweden reported on 313 patients (195 with
Crohn’s disease) who were switched from Remicade®
maintenance therapy to CT-P13 (Remsima®) and clinically
assessed after 2, 6 and 12 months [29]. No significant
changes in clinical activity, relevant biomarkers (faecal
calprotectin, C-reactive protein) and serum concentration
of infliximab (trough levels) were detected. Fourteen per-
cent of patients with Crohn’s disease and 13.8% with ulcer-
ative colitis reported disease worsening as defined by the
previously published NOR-SWITCH study [22]. Interest-
ingly, 21.2% (7/33) with Crohn’s disease and 23.8% (5/21)
with ulcerative colitis who had clinically active disease at
baseline were in clinical remission at 12 months. Similar
results on infliximab trough levels after switching have re-
cently been published from the SECURE study group [36].
After 16 weeks of CT-P13 treatment, infliximab serum
concentrations were not inferior to baseline levels, and no
significant changes in clinical and biochemical variables
were noted.
The best long-term data come from a Norwegian single-
centre cohort of 143 patients (99 Crohn’s disease) who
were switched to CT-P13 regardless of disease activity
and concomitant treatment, and followed up prospectively
for 18 months [30]. Altogether, 130 (91%) remained on
biosimilar therapy and there was no change in disease ac-
tivity scores or biomarkers.
Most recently, data from a large, real-world cohort from
France including 5050 infliximab-naïve patients with
Crohn’s disease who received either Remicade® (n = 2551)
or CT-P13 (n = 2499) have been published [41]. The com-
posite end-point (death, Crohn’s disease-related surgery,
all-cause hospitalisation, and switch to another biologic
therapy) was reached by 43.1% of Remicade® and 41.6%
of CT-P13 recipients after 1 year. Rates of serious infec-
tion, tuberculosis and solid or haematological cancers did
not differ between groups.
The first randomised data in IBD came from NOR-
SWITCH trial (see above), which investigated patients
with various immune-mediated inflammatory diseases
who were switched from Remicade® to CT-P13 and fol-
lowed up for 52 weeks [22]. For IBD, the primary endpoint
of disease worsening was defined using the Harvey-Brad-
shaw Index (4-point change from baseline; score of 7 or
greater) for Crohn’s disease and the partial Mayo Score
(3-point change from baseline; score of 5 or greater) for
ulcerative colitis. Although the primary endpoint of the
study fell within the predefined noninferiority margin of
15%, in the (underpowered) subgroup of IBD patients,
disease worsening after switching to CT-P13 was almost
significantly inferior to the reference product in patients
with Crohn’s disease. The adjusted difference in efficacy
after switching to the biosimilar was 14.3% (95% CI
12.7–3.9%), which was considered too large by many as
a clinically meaningful improvement of 12% has been de-
scribed in support of patients with immune modulator ther-
apy [35]. Recently, results from the open-label NOR-
SWITCH EXTENSION trial have been published [42].
Patients who were switched to CT-P13 after 52 weeks
were compared with patients who received CT-P13 over
the 78-week study period. In Crohn’s, disease worsening
occurred in 20.6% (13 of 63 patients) in the maintenance
group and in 13.1% (8 of 61) in the switch group; in ul-
cerative colitis, worsening occurred in 15.4% (6 of 39) and
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2.9% (1 of 35) of patients in the maintenance and switch
groups, respectively.
Results of the SIMILAR trial, a 12-week double-blind ran-
domised controlled noninferiority trial investigating the ef-
ficacy of CT-P13 in patients with Crohn’s disease and
ulcerative colitis in remission who were switched from
Remicade® are not published in full yet [61]. Preliminary
results showed that switching was feasible and safe [37].
The first head-to-head trial in IBD was a multicentre dou-
ble-blind randomised controlled phase III trial that aimed
to demonstrate noninferiority in efficacy and to assess
safety of CT-P13 against Remicade® in anti-TNF-naïve
patients with active Crohn's disease [44]. In a four-arm
design, 220 patients randomly received either CT-P13 or
Remicade® until week 30 and then either remained on the
same biological compound or switched to the other, and
were followed-up until week 54. The primary outcome was
the clinical response rate, defined as decrease in CDAI
(Crohn’s Disease Activity Index) score of >70 points at
week 6. Secondary outcome measures included clinical re-
sponse at week 30 and week 54, and clinical remission
(CDAI <150) at the same time points. Clinical response
rate was similar for CT-P13 and Remicade® at week 6 (69
vs 74%), week 30 (77 vs 75%) and week 54 (79 vs 76%).
Similar results were seen for switch patients who received
either CT-P13 (76%) or Remicade® (71%) at week 30.
One-year safety including adverse drug reactions, serious
adverse events and infections were similar among all treat-
ment groups. Also, there was no clinically meaningful dif-
ference in immunogenicity.
So far, the results of the available randomised trial are in
accordance with observational post-marketing studies that
reported positive outcomes for efficacy in both Crohn’s
disease and ulcerative colitis.
Safety considerations
Adverse events
– Frequency of adverse events is not different between pa-
tients maintained on Remicade® as compared with pa-
tients switched to CT-P13.
The clinical safety of all biologics, including biosimilars,
must be closely monitored during the post-marketing phase
to detect less common safety signals. The approval process
of biosimilars entails limited clinical exposure and certain-
ly less clinical experience than with the reference product.
Accurate data on adverse events associated with specific
treatments should be provided to treating physicians to en-
sure that the prescription of any medication is safe and ef-
fective. In Switzerland, similar pharmacovigilance require-
ments apply for biosimilars and for a new active substance
[4]. All identified and potential risks of the reference prod-
uct and the biosimilar must be taken into consideration
and a comprehensive plan for the continuing monitoring
of safety following marketing approval must be submitted
to Swissmedic. It is suggested that any pharmacovigilance
plan should also include registries of adverse drug reac-
tions that might be entered in major databases. IBDnet has
developed a nationwide independent database to monitor
biologics in IBD, including original and biosimilar prod-
ucts.
However, it is important to note that in Europe there are
currently no standard requirements for post-approval safe-
ty monitoring programmes. These programmes are devel-
oped on a national level through discussion between the
regulatory agency and the manufacturer, and already have
to be included in the initial application for regulatory ap-
proval [62–64]. A serious limitation of pharmacovigilance
is the underreporting of adverse events by healthcare
providers [65, 66].It has been suggested that even in coun-
tries with high reporting rates less than 10% of all adverse
drug reactions are reported. Successful pharmacovigilance
depends primarily on reliable reporting by treating physi-
cians.
So far, no unexpected safety issues have appeared after
several years of biosimilar use. The frequency of adverse
events for patients on CT-P13 is similar to that of patients
treated with the reference product. Currently, more than 50
studies have evaluated the efficacy, safety and immuno-
genicity consequences of switching between different
biosimilars over a range of indications in rheumatology,
dermatology and gastroenterology, and showed no relevant
difference in adverse events [25]. In a recent review in-
cluding 11, mostly open-label, studies with 1007 IBD pa-
tients (507 with Crohn’s disease) on the use of CT-P13,
9.2% of patients reported adverse side effects [67]. No dif-
ference in terms of safety was observed compared with the
reference product effect (4.1% infusion-related reactions
and 4.3% infections), which was comparable to data from
the reference product (8.2%) and in line with results from
the extension studies of PLANETAS and PLANETRA [56,
57]. Upcoming data from ongoing trials, such as SIMILAR
[68], Connect-IBD [69] and SECURE [70], will shed more
light on this topic. However, it has to be considered that
even the growing body of evidence might still be insuffi-
cient to detect rare, unexpected adverse events. Ongoing
pharmacovigilance and long-term follow-up of patients in
large databases is warranted.
Immunogenicity
– Immunogenicity is not different between patients treat-
ed with Remicade® and CT-P13. Immunogenicity is not
different between patients maintained on Remicade® as
compared with patients switched to CT-P13.
Biologics are inherently immunogenic and may elicit an-
tidrug antibodies in susceptible patients. This remains a
major safety issue that cannot be predicted in preclinical
studies. The presence of antidrug antibodies is associated
with accelerated drug clearance, more common loss of
response and higher risk of hypersensitivity reactions
[71–73]. A recent systematic review analysed 68 studies
including 14,651 patients with rheumatoid arthritis, anky-
losing spondylarthritis and inflammatory bowel disease
treated with TNF inhibitors, and found the cumulative in-
cidence of antidrug antibodies to be 12.7% (infliximab
25.3%, adalimumab 6.9%, certolizumab pegol 3.8%, goli-
mumab 1.2%) [74]. The incidence rate in IBD patients was
similar (15.8%) and in all patients concomitant immuno-
suppressive therapy reduced the risk for antidrug antibod-
ies. Overall, the presence of antidrug antibodies led to a
67% reduction of clinical response. Similar results have
been reported in patients with IBD [75].
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So far, the use of biosimilars shows similar efficacy and
safety in different patient populations, but long-term data
especially are still missing. To ensure equivalent immuno-
genicity between the biosimilar and the reference product
is still a concern [76]. Immunogenicity data for the ap-
proval of CT-P13 were mainly based on in vitro studies
and from clinical trials in rheumatology [13, 14]. Evidence
from the randomised controlled PLANETRA trial showed
a similar occurrence of antidrug antibodies after 1 year
and, in the extension study, after 2 years [56]. However,
patients in this study were all on immunosuppressive ther-
apy with methotrexate, whereas IBD patients usually have
combination therapy with azathioprine. This raises the
question as to whether it is appropriate to extrapolate im-
munogenicity data across different patient populations.
Data on immunogenicity in patients switching from Rem-
icade® to CT-P13 are limited [58]. In the NOR-SWITCH
trial, no differences in antidrug antibodies were found
overall [22] and among all the (underpowered) subgroups.
The cross-immunogenicity of CT-P13 and Remicade® in
IBD patients has elegantly been investigated in a series of
in vitro studies [77]. Sera from 125 patients (69 positive for
antidrug antibodies) and 14 healthy volunteers were tested.
Cross-reactivity experiments were repeated after deglyco-
sylation of Remicade®/CT-P13, IgG purification, excipient
dialysis and monomer purification by size exclusion chro-
matography, and antidrug antibodies were tested for their
functional inhibition of TNF-α binding to Remicade®/CT-
P13 by competition assay. All sera containing anti-Rem-
icade® antibodies were cross-reactive to Remsima® and
titres were strongly correlated (Spearman’s r 0.92–0.99 for
all experiments). In a prospective, nationwide, multicentre,
observational cohort with 353 consecutive IBD patients
(209 Crohn’s disease), biosimilar trough levels of patients
pre-exposed to a TNF inhibitor were significantly lower at
weeks 2, 14 and 30 in patients with Crohn’s disease, but
not ulcerative colitis, and were similar at week 6 and week
54 of follow-up [26]. The cumulative rate of antidrug anti-
bodies was 33.8% for all IBD patients. A higher positivity
rate at week 54 was seen only in patients with Crohn’s dis-
ease (47 vs 26%; ulcerative colitis 47 vs 32%). Recently,
the first long-term clinical data on immunogenicity in IBD
after switching to CT-P13 became available. In a single
centre prospective cohort study of 83 patients (57 Crohn’s
disease), no increase of antidrug antibodies was detected
after >2 years follow-up [78]. These findings strongly sug-
gest the presence of shared immune-dominant epitopes in
CT-P13 and infliximab originator sequences.
Clinical situations
Bio-naïve patients
– In bio-naïve patients considered for infliximab anti-
TNF therapy, treatment can be initiated with Remi-
cade®, Inflectra® or Remsima®.
Most data on the use of infliximab biosimilars in IBD
have been gathered from patients on maintenance therapy
who were switched from the original product to CT-P13,
and thus were considered exposed to an anti-TNF agent.
As outlined above, a number of prospective observational
studies, as well as randomised controlled trials have
demonstrated similar clinical efficacy, safety and immuno-
genicity of CT-P13 compared with Remicade® in these pa-
tients [15–43]. The use of infliximab biosimilars in pa-
tients naïve to TNF inhibitors is less well investigated.
A meta-analysis that included 11 smaller studies showed
response rates after induction and maintenance therapy for
Crohn’s disease (79 and 77%, respectively) and ulcera-
tive colitis (74 and 77%, respectively), comparable to those
published for Remicade® [58]. More recent data from ob-
servational cohorts have confirmed these initial results [20,
21, 26, 33, 41].
In patients with Crohn’s disease, these results have also
been confirmed by the first head-to-head trial in anti-TNF-
naïve patients with active Crohn's disease [44]. Results on
clinical response were similar up to week 54 with simi-
lar safety profiles and immunogenicity for Remicade® and
CT-P13. It can therefore be considered safe to initiate in-
fliximab therapy in bio-naïve patients with either Remi-
cade®, Inflectra® or Remsima®. Caution should be used in
patients with fistulising Crohn’s disease, since only limited
data on this patient subgroup are available [16].
Switch in class (for medical reasons)
– Patients not responding adequately to Remicade® or
losing response over time are not eligible for Inflectra®
or Remsima®.
– Patients not responding adequately to Inflectra®/Rem-
sima® or losing response over time are not eligible for
Remicade®.
– Patients not responding adequately to adalimumab or
certolizumab pegol or losing response over time are el-
igible for Remicade®, Inflectra® or Remsima®.
Of all patients starting anti-TNF therapy, 10–30% may not
respond to induction therapy (primary nonresponse), and
an additional 23–46% of patients may lose response over
time (secondary loss of response) or may become intoler-
ant to TNF inhibitors [79]. There is no consensus on the
definition of primary nonresponse, but insufficient clinical
improvement during induction therapy is clinically accept-
ed. However, the time-frame may vary depending on spe-
cific trial endpoints. Secondary loss of response is defined
as clinical relapse (assessed using clinical symptom in-
dices) during maintenance therapy after initial response to
induction [80]. For patients who do not respond (enough)
to biological therapy, dose intensification to regain ther-
apeutic effect, combination therapy with an immunosup-
pressive drug, or a switch to another biological product
may be considered. However, the latter option should only
be chosen after a thorough work-up, as in general switch-
ing between different biologics can raise safety concerns
and close monitoring of the patient is necessary. The work-
up should first confirm active inflammation with objective
methods, such as endoscopy, and infectious complications
especially should be ruled out. Serum drug levels (trough
levels) should then be measured and if not sufficient, an-
tidrug antibodies should be sought to rule out immunity
against the biological product.
Generally, low trough levels in the absence of antidrug an-
tibodies can be managed by dose optimisation, whereas
the presence of antidrug antibodies will require a switch
to another biological. As antidrug antibodies are specific
to a certain drug and do not cross-react, patients may be
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switched within the therapeutic class to another anti-TNF
agent and regain clinical response. However, patients who
develop antidrug antibodies are more prone to immuno-
genicity when exposed to a different biological product.
Biological products and their biosimilars share the same
immune-dominant epitopes. Therefore, patients who de-
velop antibodies to a reference drug with resultant loss of
clinical response should not be switched to its biosimilar.
Similarly, switching to a biosimilar is not a way to circum-
vent immunogenicity of originator [26]. If no antidrug an-
tibodies are present and the serum drug concentration is
adequate, clinical response to dose intensification is un-
likely and patients should be switched to a biological prod-
uct from another class.
Switch out of class (for medical reasons)
– Patients not responding adequately or losing response
over time to a biologic other than an anti-TNF agent
are eligible for all anti-TNF biologics or biosimilars.
For many years, TNF inhibitors were the only available bi-
ologics for treating patients with IBD. Vedolizumab and
ustekinumab are two biological agents that have been in-
troduced into the market only recently. Vedolizumab is
a humanised monoclonal gut-selective antibody against
α4β7 integrin and prevents migration of inflammatory cells
into the inflamed mucosa. Ustekinumab is a monoclonal
IgG1 antibody against the p40 subunit of interleukin‐12
(IL‐12) and interleukin‐23 (IL‐23) that targets both the
T‐helper 1 and T‐helper 17 pathways involved in the
pathogenesis of Crohn’s disease. These drugs show a clin-
ical benefit and seem to have a favourable safety profile
[81, 82]. However, like anti‐TNF agents, a significant
number of patients do not respond to these drugs. Immuno-
genicity appears less important as the development of an-
tidrug antibodies is very low for both vedolizumab (<5%)
and ustekinumab (2.3%) [83, 84]. After careful clinical
work-up, patients who do not respond adequately to bio-
logical therapy other than TNF inhibitors may be switched
to either Remicade® or CT-P13. Currently, no data on clin-
ical efficacy of TNF inhibitors as second-line therapy in
patients pre-exposed to vedolizumab or ustekinumab are
available.
Non-medical switch
– Third party payer, administrator, and regulator driven
switches from ongoing Remicade® therapy to CT-P13
are not recommended without prior approval of the pre-
scribing physician.
As outlined above, switching patients from Remicade® to
CT-P13 is regarded as clinically effective and safe on the
basis of several prospective open-label studies and ran-
domised clinical trials [15–39, 43]. The annual healthcare
costs for IBD patients have risen by 7 to 10% within the
last 10 years, largely owing to treatment expenditures dri-
ven by increased use of biological agents [85]. With a
steadily growing market, an increasing number of patients
will receive biosimilars, and safety data will have to be
continuously monitored. Overall, the biosimilars market
has increased its value worldwide from around $2.5 bil-
lion in 2017 to $4.5 billion by the end of 2018 and is
expected to expand to $61 billion by 2025 at an annual
growth rate of 34% [86]. Given the large economic burden
of biologic treatment of IBD, the main purpose of pro-
ducing biosimilars is to reduce costs. In Central and East-
ern Europe, the introduction of CT-P13 has resulted in a
20–60% price reduction for infliximab [87] and in Norway
a 69% discount was offered for CT-P13 compared with
Remicade® for its national supply in 2015 [88]. As more
biosimilars enter the market, competition will further re-
duce prices, also for the original reference product. How-
ever, 56% of patients stated in a recent survey that safety
and efficacy should be more important than lower cost
of biosimilars [89]. In some countries, such Australia and
Germany, automatic substitution is allowed for a select
list of biosimilars, and in Germany patients have to pay
the difference between the retail price and the reference
reimbursement price, giving them an incentive to choose
the cheaper (biosimilar) drug. Manufacturers are free to
set a price for biosimilars in the US, Germany and the
UK whereas other countries prohibit or limit manufacturer
discounts [90]. In the US, insurance companies can in-
crease biosimilar adoption rates by providing physicians
with easy access to biosimilars (prior authorisation, pre-
certification) while maintaining the administrative burden
for the reference product [91]. In Switzerland, this policy
has not been adopted. Healthcare providers in Switzerland
are currently the only beneficiaries of switching a patient
from a reference product to a less-expensive biosimilar.
The risks inherent to drug switching are solely taken by the
patient without having any financial benefits. Non-medical
switch driven by third party payers, administrators and/or
regulators in patients who have responded well to Remi-
cade® should therefore be avoided.
Practical aspects – dosing, infusion manage-
ment and monitoring
– Handling and administration of Inflectra® and Remsi-
ma® are similar to those of Remicade®. Dose and ad-
ministration interval of Remicade® should be main-
tained if a patient is switched to a biosimilar.
– Laboratory tests to detect anti-infliximab antibodies
and infliximab trough levels are sensitive to Remicade®,
Inflectra® and Remsima®
The approval of biosimilars is based on clinical data that
apply the same dose recommendations and route of admin-
istration as for the reference product. Once regulatory ap-
proval is granted, the same dose recommendations as for
the original product can then be used for the biosimilar in
all other indications. Also, storage and preparation, as well
as infusion regimens, are identical for the reference prod-
uct and corresponding biosimilar.
When switching from a biologic to the respective biosimi-
lar, dose and treatment interval should be maintained. The
available data show similar clinical efficacy after switch-
ing to a biosimilar without the need for dose adjustments
[29]. Laboratory tests developed to measure infliximab
trough levels and detect antidrug antibodies are equally
sensitive for the reference product and any biosimilar. In
a recent publication, 180 samples of 34 patients (16 pa-
tients with Crohn’s disease) and 28 infliximab-naïve con-
trols (12 patients with Crohn’s disease) were analysed [92].
Seventy-six samples tested positive for antibodies to Rem-
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icade®. Samples were then retested using a CT-P13 or a
SB2 bridging assay and again all tested positive for inflix-
imab antibodies resulting in 100% test agreement. Spear-
man’s correlation was 0.98 for all comparisons, showing
almost perfect alignment.
Patient perspectives
– Many patients are not sufficiently informed about
biosimilars, and thus are not familiar with the treat-
ment. The decision to start biologic or biosimilar ther-
apy should be taken in partnership with the patient.
In Switzerland, as in many other countries, automatic sub-
stitution of biologics and biosimilars is discouraged by the
regulatory authority, leaving the decision to interchange
biological products with the prescribing physician. Any
major treatment decision should always be taken in part-
nership with the patient, especially when highly potent bi-
ological medical products are introduced. The information
presented to the patient should be transparent and com-
prehensive. Patients also have an obligation to engage in
this discussion and participate actively in decision-making
about their own therapy. However, a recent survey by the
European Crohn’s and Colitis Organization (ECCO) clear-
ly demonstrated that patients are not familiar with many
aspects of biological therapies including biosimilars [89].
Of 1181 participants, 62% had never heard of biosimi-
lars and 40% of patients and 27% of patient associations
felt they should be systematically informed. Their main
concern was about safety (47%) and efficacy of treatment
(40%), whereas only 31% had no concerns using biosimi-
lars.
In order to make informed and appropriate treatment de-
cisions with their patients, clinicians must understand the
attributes and potential risks and benefits of biosimilars. In
an anonymous survey among member of ECCO in 2013,
61% of participants felt little or no confidence in using
biosimilars in their everyday clinical practice, regarded
cost saving (89%) as the main advantage; extrapolation
of indications and interchangeability of biosimilars were
mentioned as main concerns [11]. In 2016, the survey was
again sent out to ECCO members [12]. Interestingly, only
a minority (19.5%) felt little or no confidence in the use
of biosimilars, whereas cost saving (92.4%) was now men-
tioned as the main advantage and immunogenicity re-
mained a main concern with biosimilars. Similar results
were obtained in a survey among rheumatologists, derma-
tologists and gastroenterologists in the US, in which 84%
of participants did not want to switch to biosimilars in
stable patients and anticipated a negative impact on pa-
tient mental health (59%), treatment efficacy (57%), pa-
tient safety (53%) and physician office management (60%)
[93].
Clearly, there is a need for education of patients and physi-
cians alike. Effective communication needs to be ad-
dressed as shared decision making between healthcare pro-
fessionals and patients will be a key aspect in order for
biosimilars to be integrated effectively into clinical prac-
tice.
Discussion and next steps
In the near future we shall see an almost exponential
growth of the biosimilar market with the introduction of a
number of new products. After the introduction of CT-P13
in Switzerland, marketed as Inflectra® and Remsima®, IBD
patients will soon be exposed to more infliximab biosimi-
lars and also biosimilars of adalimumab and other biolog-
ics.
Biosimilars have several advantages: they reduce cost by
competition with the original product; they offer enhanced
accessibility to more affordable treatment options; and for
companies they provide an incentive for innovative and
patentable new biological product to maintain their market
share in the future. However, biosimilars face a number
of challenges. In order to gain wide acceptance, education
of patients and healthcare providers should be the primary
goal. Patients lack substantial knowledge on key aspects of
biosimilars, which makes shared decision making difficult
for doctors who are also still not completely comfortable
with biosimilars. The concepts of extrapolation and in-
terchangeability and uncertainties about patient safety are
particular cause for concerns for many. More clinical data
are needed to identify the ideal patient to receive or to be
switched to a biosimilar. Also, switching between different
biosimilars and multiple switching of originators and vari-
ous biosimilars is a possible scenario for future patient care
that is driven by fast development of new biosimilar mole-
cules with likely reduction of treatment cost. However, this
should be evaluated very carefully, as comparability be-
tween new biosimilars will not be tested at all. Therefore,
regulatory legislation should be standardised and provide
harmonised naming of biosimilars, clarify the directives on
interchangeability of biological products and enable effi-
cient pharmacovigilance. Long-term observational studies
especially are recommended to improve the safety profile
of biosimilars and increase confidence among patients and
physicians.
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